Challenges and Future Perspectives of Immunotherapy in Pancreatic Cancer.

Cancers (Basel) · 2021 · PMC8391691 · PMID 34439389

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Final data from this phase II clinical trial reported a positive trend in mean overall survival (mOS) for patients treated with neoadjuvant GVAX alone (35.0 months compared to 24.8 months in historical controls) in comparison with patients who were additionally treated with cyclophosphamide (mOS 15.4 and 16.5 months) [ 29 ].

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.